12 th Update on the Management of Genitourinary Malignancies (Formerly named Urologic Oncology: Advances in Clinical Practice)

Transcription

1 12 th Update on the Management of Genitourinary Malignancies (Formerly named Urologic : Advances in Clinical Practice) October 13-14, 2017 The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB), Floor 8, Rooms Pressler Street Houston, Texas

2 Focus The 12th Update on the Management of Genitourinary Malignancies Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced cancers of the bladder, prostate and kidney. Educational Objectives After attending the conference, participants should be able to Access treatment and management options for patients with rare genitourinary malignancies and be able to better counsel patients on these options (Knowledge, Competence, Performance, Patient Outcomes); Incorporate neoadjuvant therapy in the management of renal cell carcinoma (Knowledge, Competence, Performance); 12 th Update on the Management of Genitourinary Malignancies Implement and illustrate clinical advances in the treatment approach to localized, locally advanced and metastatic prostate cancer (Knowledge, Competence, Performance); Access the best treatment option for urothelial carcinoma and incorporate emerging and novel techniques to provide optimal patient care (Knowledge, Competence, Performance, Patient Outcomes). Educational Methods Lectures Case Presentations Panel Discussions Audience Response System Question and Discussion Sessions Poster Session Target Audience This conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants. Evaluation A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. Accreditation/ Credit Designation The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME Certificates and Attendance Verification Certificates Certificates awarding AMA PRA Category 1 Credit or certificates documenting attendance will be distributed to participants as they depart the symposium. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations. Physician Payments Sunshine Act MD Anderson complies with the Physicians Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

3 Call for Abstracts Abstracts will be selected for poster presentation at the conference. Please submit abstracts via to The deadline for submission is August 25, Authors of selected abstracts will be notified via by September 30, Program MD Anderson Organizing Committee Conference Chairs Christopher G. Wood, MD Program Chairman and Vice Chairman Program Co-Chairman and Vice Chairman Program Co-Chairman Assistant Conference Committee Ana Aparicio, MD John W. Davis, MD Colin P. Dinney, MD and Chairman Jose A. Karam, MD Neema Navai, MD Assistant Curtis A. Pettaway, MD Arlene O. Siefker-Radtke, MD Carol Fourtunia Administrative Coordinator Constance C. Tierney, CMP Manager CME/Conference Management Friday, October 13, :30 a.m. Registration and Continental Breakfast 8:25 Welcome and Opening Remarks Christopher G. Wood, MD Session I: Rare Genitourinary Cancers and Benign in the Cancer Patient Moderator: Curtis A. Pettaway, MD 8:30 Update on the Management of Advanced Testicular Cancer Shi-Ming Tu, MD 9:00 Update on the Management of Adrenocortical Carcinoma Amishi Y. Shah, MD 9:30 Update on the Management of Locally Advanced and Metastatic Penile Cancer Curtis A. Pettaway, MD 10:00 Questions and Answers 10:10 Break 10:30 Treatment of Locally Advanced Upper Tract Transitional Cell Carcinoma: The Rationale for Neoadjuvant Chemotherapy Surena F. Matin, MD 11:00 Urinary Diversion Options After Radical Cystectomy: Tips and Tricks William J. Graber, MD

4 11:30 Dealing With Benign Urologic Issues in the Cancer Patient: The MD Anderson Experience William J. Graber, MD Noon Questions and Answers 12:10 p.m. Lunch (Provided) 1:05 The Andrew C. von Eschenbach Lectureship Introduction: Colin P. Dinney, MD; Christopher G. Wood, MD; ; Session II: Renal Cell Carcinoma Moderator: Jose A. Karam, MD 1:35 AUA/ASCO/EAU/NCCN Guidelines for the Small Renal Mass: Which One Should We Adopt? Mehrad Adibi, MD 1:55 When is a Biopsy Indicated for the Small Renal Mass in 2017? Surena F. Matin, MD 2:15 Imaging for Renal Masses: What Should We Use in 2017? Aradhana M. Venkatesan, MD 2:35 Ablative Therapy for the Small Renal Mass: An Update Sharjeel H. Sabir, MD 2:55 Questions and Answers 3:00 Break 3:20 Adjuvant Therapy for Renal Cell Carcinoma in 2017: Ready for Primetime? Jose A. Karam, MD 3:40 The Role of Lymphadenectomy for Renal Cell Carcinoma in 2017: Is It Necessary? Jeffrey J. Tomaszewski, MD 4:00 Debate: Partial Nephrectomy for T1b Renal Tumors Pro: Christopher G. Wood, MD Con: Surena F. Matin, MD 4:30 What is the Standard of Care and Available Options in Front Line and Second Line Therapy and Beyond for Metastatic Renal Cell Carcinoma? Eric Jonasch, MD 4:50 What is Available for Non-Clear Cell Histology Metastatic Renal Cell Carcinoma? 5:10 The Promise of Immunotherapy in Metastatic Renal Cell Carcinoma and Novel and Promising Emerging Therapies Jianjun Gao, MD, PhD 5:30 Case Presentations Moderator: Christopher G. Wood, MD Panel: Urologic and Medical Faculty 6:00 p.m. Welcome Reception Saturday, October 14, :30 a.m. Registration and Continental Breakfast 8:25 Welcome and Announcements Christopher G. Wood, MD Session III: Bladder Cancer Non-Muscle Invasive Bladder Cancer Moderator: Neema Navai, MD 8:30 Debate: What is the Best Treatment Option for Patients With Disease After Receiving BCG? Continued Conventional Intravesical Therapy With an Altered Regimen Ashish Kamat, MD Novel Immunotherapeutic Agents/Gene Therapy Colin P. Dinney, MD Radical Cystectomy Neema Navai, MD 8:50 Debate: What is the Best Approach to Intermediate Risk NMIBC? Intravesical Chemotherapy Mehrad Adibi, MD BCG Scott Delacroix, MD

5 9:10 NIMBC Case Discussions Moderator: Ashish Kamat, MD Panel: Urologic Faculty Muscle Invasive Bladder Cancer and Upper Tract Disease Moderator: Neema Navai, MD 9:25 Debate: RPLND is Mandatory During Nephroureterectomy Pro Surena F. Matin, MD Con Jose A. Karam, MD 9:40 Questions and Answers 9:50 Break 10:00 Debate: What is the Best Management for the Patient With ct2 Bladder Cancer Who Refuses Cystectomy? Trimodal Therapy Seungtaek Choi, MD Radical TURBT Ashish Kamat, MD Partial Cystectomy With PLND Colin P. Dinney, MD 10:20 MIBC and Upper Tract Cases Moderator: Neema Navai, MD Panel: Urologic, Radiation and Medical Faculty Locally Advanced and Metastatic Urothelial Carcinoma Moderator: Arlene O. Siefker-Radtke, MD 10:40 Debate: What is the Best Immunotherapy Regimen for Urothelial Cancer: PD1 or PDL1 Inhibition Jianjun Gao, MD, PhD Combination Therapy With Anti CTLA4 and PD1 or PDL1 Inhibition Arlene O. Siefker-Radtke, MD 11:00 Debate: What is the Best Initial Systemic Therapy? Immunotherapy Jianjun Gao, MD, PhD Platinum Based Chemotherapy Amishi Y. Shah, MD 11:20 Systemic Therapy in Localized Disease Case Discussions: Managing Toxicity Moderator: Arlene O. Siefker-Radtke, MD Panel: Medical Faculty 11:40 The Changing Landscape of Systemic Therapy: New Agents and Novel Therapies Arlene O. Siefker-Radtke, MD 11:50 Locally Advanced and Metastatic Urolothelial Cancer Case Discussions Moderator: Amishi Y. Shah, MD Panel: Urologic, Radiation, and Medical Faculty 12:10 p.m. Questions and Answers 12:15 Lunch (Provided) 1:00 MACRA, MIPS and the Urologist: The Alphabet Soup of the Changing Healthcare Landscape and Why We Need to Know About It Mehrad Adibi, MD Distinguished Alumni Lectures Moderator: ; Nizar Tannir, MD 1:15 David A. Swanson Distinguished Alumni Lecture Series Peter Black, MD 1:40 Distinguished Alumni Lecture Avishay Sella, MD Session IV: Prostate Cancer Moderator: 2:00 PSA Screening: A Reboot From the USPSTF John W. Davis, MD 2:15 Critique, Questions, and Answers Curtis A. Pettaway, MD 2:20 Challenging Cases in Prostate Biopsy Part 1 Leonard Gomella, MD 2:35 Challenging Cases in Prostate Biopsy Part 2 John W. Davis, MD

6 MD Anderson Faculty 2:50 Surgery for Localized Disease: Impact on Survivor and Quality of Life Louis L. Pisters, MD 3:00 Critique, Questions, and Answers Steven J. Frank, MD 3:05 Break 3:10 Control of the Primary Tumor in the Setting of Metastatic Disease: Update on Clinical Trials and What To Do Now 3:25 Critique, Questions, and Answers Ana Aparicio, MD; Christopher J. Logothetis, MD 3:30 Radiation Therapy for Prostate Cancer Update: A Physicists Point of View Rajat J. Kudchadker, PhD 3:45 Critique, Questions, and Answers Steven J. Frank, MD 3:50 High Risk Prostate Cancer: The Neoadjuvant Therapy Narrative Eleni Efstathiou, MD, PhD 4:05 Critique, Questions, and Answers Ana Aparicio, MD; Christopher J. Logothetis, MD 4:10 Critique, Questions, and Answers ; John W. Davis, MD 4:15 Case Discussions Moderator: Panel: Mitchell S. Anscher, MD; Ana Aparicio, MD; John W. Davis, MD; Eleni Efstathiou, MD, PhD; Steven J. Frank, MD; Curtis A. Pettaway, MD; Louis L. Pisters, MD; John F. Ward, MD 4:35 Adjourn Mehrad Adibi, MD Assistant Mitchell S. Anscher, MD Radiation Ana Aparicio, MD Assistant Seungtaek Choi, MD Radiation John W. Davis, MD Colin P. Dinney, MD and Chairman Eleni Efstathiou, MD, PhD Steven J. Frank, MD Radiation Jianjun Gao, MD, PhD Assistant William J. Graber, MD Eric Jonasch, MD Ashish Kamat, MD Jose A. Karam, MD Rajat J. Kudchadker, PhD Radiation Physics Christopher J. Logothetis, MD Chair and Surena F. Matin, MD Neema Navai, MD Assistant Curtis A. Pettaway, MD Louis L. Pisters, MD Amishi Y. Shah, MD Assistant Sharjeel H. Sabir, MD Assistant Interventional Radiology Arlene O. Siefker-Radtke, MD and Vice Chairman Shi-Ming Tu, MD Aradhana M. Venkatesan, MD Diagnostic Radiology John F. Ward, MD Christopher G. Wood, MD and Vice Chairman

7 Guest Faculty Scott Delacroix, MD LSU Health Metairie, Louisiana Andrew C. von Eschenbach Lecture Series Leonard Gomella, MD Chairman Department of Thomas Jefferson University Hospital Philadelphia, Pennsylvania Distinguished Alums David A. Swanson Distinguished Alumni Lecture Series Alumnus: Peter Black, MD Department of Urologic Sciences University of British Columbia Vancouver, Canada GU Medical Alumna: Avishay Sella, MD Head Department of Asaf Harofeh Medical Center Zerifin, Israel Jeffrey J. Tomaszewski, MD Assistant Surgery Assistant Director Genitourinary MD Anderson Cancer Center at Cooper Camden, New Jersey The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth. Registration Information On-site registration opens at 7:30 a.m. on Friday, October 13, The conference will begin at 8:25 a.m. on Friday, October 13, 2017 and adjourn on Saturday, October 14, 2017 at 4:35 p.m. Advanced registration is encouraged as space and materials are limited. Please see the registration form for applicable fees. The full conference registration fee includes the tuition, program, USB, continental breakfasts, breaks, lunches, and reception. The deadline for advance registration is Friday, September 29, There are three ways to register: 1. On-line at conferences 2. Fax to: Mail to: CME/Conference Management Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box Houston, TX We accept the following forms of payment: 1. Check (payable through U.S. banks only) 2. Money Order 3. Credit Cards (MasterCard, VISA, and American Express) 4. Cash (on-site registration only) When registering online a receipt/ confirmation letter will be automatically ed to the address you list on the registration form. If you register by fax or mail, a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee. Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before September 29, No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, , or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. Photographing, audio taping and videotaping are prohibited.

8 The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Special Assistance Contact the Department of CME/ Conference Management at or toll free at if you have any special dietary or ADA accommodation needs. Accommodations A block of rooms has been reserved for conference attendees at the Houston Marriott Medical Center, 6580 Fannin Street, Houston, Texas. Early hotel reservation is suggested. To make reservations, please call Reservations at and identify yourself as part of the MD Anderson Urologic Conference The special meeting rate is $ single or double occupancy. Please add 17% Texas State and local taxes. Reservations and deposits received after September 21, 2017 will be confirmed if space is available and at current hotel published guest room rates. Ground Transportation (prices are subject to change and variable depending on location of conference) Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). Taxicabs are available at an estimated cost for $50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport. Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott Medical Center for $27 one-way and $54 roundtrip. For more information, call or toll-free at or on-line at Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott Medical Center for $24 one-way and $48 round-trip. For more information, call or toll-free at or on-line at Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration. CONFERENCE REGISTRATION /30/116324/41 12th Update on the Management of Genitourinary Malignancies October 13-14, 2017 THIS IS NOT A SELF-MAILER - Address to: 12th Update on the Management of Genitourinary Malignancies October 13-14, 2017 Department of CME/Conference Management Unit 1781 The University of Texas MD Anderson Cancer Center PO Box , Houston, TX or fax to Make check or money order payable to: The University of Texas MD Anderson Cancer Center Last Name First MI Highest Degree Department (include unit no.) Specialty Institution MD Anderson Employee ID No. (required for all MDACC employees): Physician Yes No Street City State/Foreign Country/Zip or Mail Code GENERAL CONFERENCE REGISTRATION FEES Daytime Phone (with area code) Cell Phone (with area code) Fax (with area code) Physicians/Scientists 1 Postmarked before September 29, $ Postmarked after September 29, $ Address (please print) Emergency Contact Phone (with area code) Charge the following: VISA MasterCard American Express Students / Trainees / PAs / Advanced Nurse Practitioners 1 Postmarked before September 29, $ Postmarked after September 29, $80.00 Credit Card Holder Name (First/Last) Credit Card Holder Billing Address & ZIP Code Credit Card Number Expiration Date MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted Business Unit Department Fund Group* Fund Fund Type Authorized Signature REQUIRED for credit card or IDT IDT Approver Name (First/Last) please print

9 Department of CME/Conference Management - Unit 1781 The University of Texas MD Anderson Cancer Center #176700/30/116324/41 PO Box Houston, TX Non-Profit Org. U.S. Postage PAID Permit No Houston, TX